Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

Share this content:
R-CHOP is a standard front-line treatment for patients with follicular lymphoma, and previous studies indicate that lenalidomide plus rituximab is also highly effective.
R-CHOP is a standard front-line treatment for patients with follicular lymphoma, and previous studies indicate that lenalidomide plus rituximab is also highly effective.

Lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) was safe and effective as first-line treatment for patients with follicular lymphoma (FL), according to a study published in The Lancet Haematology.

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for patients with follicular lymphoma, and previous studies have shown that lenalidomide plus rituximab is a highly effective option as well. The effectiveness of using these 2 regimens in combination requires further study.

For this phase 2 study, researchers enrolled 80 patients with previously untreated high-burden FL. Induction therapy consisted of 6 cycles of R2-CHOP every 3 weeks followed by 2 rituximab infusions.

Results showed that 68 (85%) of study enrollees completed all 6 cycles of R2-CHOP. Overall, 75 of the 80 patients achieved an objective response; by the end of the induction phase, 59 (74%) and 16 (20%) had complete (CR) and partial responses (PR), respectively. At 30 months after enrollment, 55 (69%) patients had a CR.

The most frequently observed grade 4 adverse event (AE) was neutropenia, which occurred in 52 (65%) of patients. Nonhematologic AEs included grade 1 to 2 sensory neuropathy and transient rash.

R2-CHOP treatment had adequate safety and good clinical activity among patients with high-burden FL. The authors concluded that “a future comparative study showing evidence of a survival advantage would be necessary for this combination to be proposed as a treatment for follicular lymphoma.”

Reference

Tilly H, Morschhauser F, Casasnovas O, et al. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study [published online September 1, 2018]. Lancet Haematol. doi: 10.1016/S2352-3026(18)30131-5

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs